Introduction
Gastrointestinal cancers represent a significant global health burden, with colorectal and pancreatic cancers among the leading causes of cancer-related morbidity and mortality. Recent advances in immunotherapy, targeted therapies, and combination regimens are reshaping management paradigms. This article critically examines recent key clinical trial highlights discussed by Dr. Benjamin Weinberg from the Lombardi Comprehensive Cancer Center, focusing on neoadjuvant immunotherapy, novel antibody-drug conjugates, and combination systemic therapies in advanced gastrointestinal malignancies.
